A biotech start-up will develop six new small molecules with the help of $120 million in new funding. Superluminal Medicines is using generative artificial intelligence to help design small-molecule ...

Whenever I interview the founders of a new biotech company, I typically inquire about the origin of the company’s name. There is an astonishingly wide range of responses to this question. A few days ...

Eli Lilly and Co LLY has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.